Servier's Estève Speranza outlines the rationale behind the French group's reorganisation in the Nordic countries, how the global shift towards oncology is playing out in his region, and the Nordics' relevance to Servier as an innovation hub and home to its antibody centre of excellence.
Servier is actively looking for further partnerships and acquisitions worldwide, including in the Nordic region due to its high level of innovation
Lars Georg Rust outlines Olympus’ transition into fully-fledged MedTech company, the relevance of the Nordics and Netherlands to the global group, and some areas for improvement within the Danish hospital…
Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is…
GN Hearing CEO Gitte Aabo highlights the significant unmet needs of hearing impairment patients, the role of private companies like GN in fighting against stigmas surrounding hearing aids, the digital…
Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed…
Catherine Mazzacco’s two-year stint as CEO of Danish dermatology specialist LEO Pharma is over. With the company’s board planning for an initial public offering (IPO) within the next four-to-five years,…
Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international…
See our Cookie Privacy Policy Here